AbbVie to Acquire Allergan for $63B

AbbVie to Acquire Allergan for its Portfolio in Medical Aesthetics and Ophthalmology for $63B


  • AbbVie to acquire Allergan in cash & stock transaction making the total deal value $63B, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. The transaction represents a 45% premium to the closing price of shares of Allergan on June 24, 2019
  • Allergan shareholders to receive 0.8660 shares in AbbVie and $120.30 in cash for each share in Allergan for a total consideration of $188.24/share of Allergan. The focus of the acquisition is to expand AbbVie’s revenue base with addition of Allergan’s medical aesthetics and ophthalmology portfolio
  • Post-acquisition AbbVie’s shareholder will own ~83% of AbbVie and Allergan’s shareholders will own ~17% of AbbVie on a fully diluted basis. The transaction is expected to close in H1’20

Click here to read full press release/ article | Ref: AbbVie | Image: Allergan